Insider Shareholders with Direct Ownership of Cytom X Therapeutics, Inc. (CTMX)
This section provides a comprehensive overview of the insiders with direct ownership of Cytom X Therapeutics, Inc. (CTMX). You can find detailed information about the size and nature of each insider's ownership stake, as well as the latest updates on their holdings.
CytomX Therapeutics, Inc. Insider List
| Insider | Adquired | Disposed | Held | # of Trades | Last Transaction |
|---|---|---|---|---|---|
| 935,317 | 188,805 | 657,851 $717,057 | 23 |
Aug 20, 2024
Reduced 2.07%
|
|
|
Marcia Belvin
SVP, Chief Scientific Officer |
120,000 | 25,172 | 175,648 $191,456 | 9 |
Aug 20, 2024
Reduced 2.32%
|
|
Lloyd A Rowland
General Counsel |
125,000 | 26,651 | 130,797 $142,568 | 13 |
Aug 20, 2024
Reduced 3.1%
|
|
Jeffrey B Landau
Chief Business Officer |
115,000 | 24,622 | 119,056 $129,771 | 12 |
Aug 20, 2024
Reduced 3.39%
|
|
Christopher Ogden
Chief Financial Officer |
96,250 | 7,461 | 108,077 $117,803 | 9 |
Aug 20, 2024
Reduced 1.8%
|
|
Amy C. Peterson
EVP, Chief Development Officer |
66,421 | 11,720 | 58,433 $63,691 | 6 |
Mar 16, 2023
Reduced 6.79%
|
|
Carlos Campoy
Chief Financial Officer |
43,921 | 5,697 | 38,224 $41,664 | 6 |
Mar 16, 2023
Reduced 4.37%
|
|
Alison L. Hannah
Chief Medical Officer |
37,500 | 5,602 | 31,898 $34,768 | 3 |
Jul 20, 2022
Reduced 14.94%
|
|
Yu Waye Chu
Chief Medical Officer |
26,250 | 0 | 26,250 $28,612 | 1 |
Jan 18, 2024
Added 50.0%
|
| 5,000 | 0 | 5,142 $5,604 | 1 |
Mar 29, 2023
Added 49.3%
|